Cellectis soars as Pfizer fronts $80m for immuno-oncology

Pfizer is paying $80m up front to French company Cellectis for access to its CAR-T platform, an allogeneic cell therapy approach to treating cancer with the aim of developing 'off-the-shelf' immunotherapies. Cellectis's Chimeric Antigen Receptor T-cell (CAR-T) technology uses engineered T-cells from a single donor for use in multiple patients, compared with autologous approaches which require engineering of a patient's own T-cells to target tumor cells.